These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8642918)

  • 1. [Cytokines slow down the progression of MS. Successful animal experiments with a vaccine].
    Orn P
    Lakartidningen; 1996 Feb; 93(7):573-5. PubMed ID: 8642918
    [No Abstract]   [Full Text] [Related]  

  • 2. Magnetic resonance imaging as an outcome measure in the treatment of multiple sclerosis: results of the interferon beta trial.
    Koopmans RA; Paty DW
    Mult Scler; 1995; 1 Suppl 1():S22-3. PubMed ID: 9345393
    [No Abstract]   [Full Text] [Related]  

  • 3. [Multiple sclerosis: epidemiology, molecular pathology and therapy].
    Steck AJ; Schaeren-Wiemers N
    Schweiz Med Wochenschr; 1999 Nov; 129(46):1764-8. PubMed ID: 10603650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent progress in treatment for multiple sclerosis].
    Kira J
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1261-3. PubMed ID: 11464473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis.
    Agius MA
    West J Med; 1995 Nov; 163(5):473. PubMed ID: 8533414
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current developments in the area of multiple sclerosis].
    Polman CH; Koetsier JC
    Ned Tijdschr Geneeskd; 1994 Jan; 138(1):10-6. PubMed ID: 8289951
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial.
    Fernández O; Antiquëdad A; Arbizu T; Capdevíla A; de Castro P; Correa de Sa JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X
    Mult Scler; 1995; 1 Suppl 1():S67-9. PubMed ID: 9345404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-beta therapy for multiple sclerosis--is the injection site the relevant action site?
    Smith D
    J Neuroimmunol; 2009 Oct; 215(1-2):117-21. PubMed ID: 19773087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
    Hermans G; Denzer U; Lohse A; Raus J; Stinissen P
    J Autoimmun; 1999 Sep; 13(2):233-46. PubMed ID: 10479392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: human model for EAE?
    Hohlfeld R
    Eur J Immunol; 2009 Aug; 39(8):2036-9. PubMed ID: 19672899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
    Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
    Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A
    Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal models for multiple sclerosis.
    Owens T
    Adv Neurol; 2006; 98():77-89. PubMed ID: 16400828
    [No Abstract]   [Full Text] [Related]  

  • 15. The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy.
    Kieseier BC; Archelos JJ; Storch M; Gold R; Hartung HP
    Wien Klin Wochenschr; 1999 Sep; 111(17):728-37. PubMed ID: 10526397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a factor from multiple sclerosis serum on isolated T and B lymphocytes.
    Armentrout SA; Sweet PM; Galant SP
    J Clin Lab Immunol; 1981 May; 5(3):133-6. PubMed ID: 6972451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy.
    Becher B; Giacomini PS; Pelletier D; McCrea E; Prat A; Antel JP
    Ann Neurol; 1999 Feb; 45(2):247-50. PubMed ID: 9989628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of multiple sclerosis: where are we? Where should we go?
    Martin R; Stürzebecher CS; McFarland HF
    Nat Immunol; 2001 Sep; 2(9):785-8. PubMed ID: 11526386
    [No Abstract]   [Full Text] [Related]  

  • 20. What transgenic and knockout mouse models teach us about experimental autoimmune encephalomyelitis.
    Fazekas G; Tabira T
    Rev Immunogenet; 2000; 2(1):115-32. PubMed ID: 11324684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.